11/27
07:09 am
cgen
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies [Yahoo! Finance]
Medium
Report
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies [Yahoo! Finance]
11/27
07:00 am
cgen
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Medium
Report
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
11/15
05:29 am
cgen
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? [Yahoo! Finance]
Medium
Report
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? [Yahoo! Finance]
11/13
02:14 am
cgen
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... [Yahoo! Finance]
Low
Report
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... [Yahoo! Finance]
11/12
07:00 am
cgen
Compugen Reports Third Quarter 2024 Results
Medium
Report
Compugen Reports Third Quarter 2024 Results
11/11
07:00 am
cgen
Compugen to Participate in Stifel 2024 Healthcare Conference
Low
Report
Compugen to Participate in Stifel 2024 Healthcare Conference
11/5
09:00 am
cgen
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
Neutral
Report
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
10/29
07:00 am
cgen
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Neutral
Report
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/7
07:00 am
cgen
Compugen to Present New Clinical Data at SITC 2024
Low
Report
Compugen to Present New Clinical Data at SITC 2024